CytomX TherapeuticsCTMX -1.36%36 Median PS Value is $1.47 as of Jun. 25, 2026, which is 259% above its 10-year median of 0.41. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 277 Biotechnology companies, CytomX Therapeutics ranks worse than 90.25% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for CytomX Therapeutics's Median PS Value or its related term are showing as below:
CTMX'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05 Med: 0.41 Max: 3.2
Current: 2.23
During the past 13 years, the highest Price to Median PS Value of CytomX Therapeutics was 3.20. The lowest was 0.05. And the median was 0.41.
CTMX's Price-to-Median-PS-Value is ranked worse than 90.25% of 277
companies
in the Biotechnology industry
Industry Median: 0.63
vs CTMX: 2.23
CytomX Therapeutics (NAS:CTMX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
CytomX Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
3.275
/
1.47
=
2.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytomX Therapeutics Median PS Value Related Terms
CytomX Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for CytomX Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTMX vs SMNR, AURA, OMER: Median PS Value Comparison
For the Biotechnology subindustry, CytomX Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.0494.
CytomX Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.243.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytomX Therapeutics (CTMX) has a Median PS Value of $1.47 as of Jun. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on CytomX Therapeutics and its competitors. This is 259% above median its historical median of 0.41. Over the past decade, CytomX Therapeutics' Median PS Value has ranged from 0.05 to 3.20. According to the industry distribution chart, CytomX Therapeutics ranks #250 out of 277 companies in the Biotechnology industry, placing it in the top 90.3%.
Is CytomX Therapeutics' Median PS Value too high?
CytomX Therapeutics' current Median PS Value of $1.47 is 259% above median its 10-year median of 0.41. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 3.20. The Biotechnology industry median Median PS Value is 0.63. CytomX Therapeutics' value of $1.47 is 133.3% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #250 out of 277 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Median PS Value compare to SMNR and AURA?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #250 out of 277 companies for Median PS Value. This places CytomX Therapeutics in the lower half of its industry. The industry median Median PS Value is 0.63. CytomX Therapeutics' value of $1.47 is 133.3% above this benchmark. Historically, CytomX Therapeutics' own Median PS Value has ranged from 0.05 to 3.20 over the past decade. While the company's 10-year median is 0.41 vs. the industry median of 0.63, CytomX Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Median PS Value of $1.47 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on CytomX Therapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Median PS Value is $1.47, which is 259% above median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.28 — trading 1069.6% above its estimated fair value. The current Median PS Value is $1.47, which is 259% above median its 10-year median of 0.41 and 133.3% above the Biotechnology industry median of 0.63. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Median PS Value is $1.47 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytomX Therapeutics (CTMX) Overvalued in 2026?
Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued.
The current stock price of $3.28 is trading 1069.6% above its estimated GF Value™ of $0.28.
GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.
Key valuation signals for CTMX:
Median PS Value: $1.47 (259% above median its 10-year median of 0.41)
GF Value™: $0.28 vs. price of $3.28 (1069.6% above fair value)
Industry Position: 133.3% above the Biotechnology median (#250 of 277)
No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score
Get the complete analysis for CTMX
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTMX has been successfully added to your 
